Hammes Company and Foley hosted a complimentary, one-hour, in-depth Web conference on Nov. 14, 2013, that detailed keys to the successful execution of a strategic ambulatory plan for hospitals and health systems.
During this session, the panel explored:
- Current industry trends as related to mergers, acquisitions, affiliations, and alignments and their impact on the ambulatory environment
- Real estate strategies, including adopting a retail mindset, analyzing the lowest cost of occupancy, evaluating third-party financing options, and considering the best sites to place services to optimize the performance of every location
- Physician onboarding, operational prototyping, efficiency improvement efforts, and organizational structures that can be applied across a network of multiple sites of care
- Legal and regulatory hurdles related to executing an ambulatory strategy
Panelists
Roger D. Strode, Partner, Foley & Lardner LLP
Ted Carson, National Director of Real Estate Advisory Services, Hammes Company
Rebecca Flink, Practice Leader, Hammes Company
Moderator
Mark Coughlin, Senior Vice President, Hammes Company
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.